These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8335037)

  • 21. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.
    Valentin JP; Bass AS; Atrakchi A; Olejniczak K; Kannosuke F
    J Pharmacol Toxicol Methods; 2005; 52(1):22-9. PubMed ID: 15961324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.
    Louizos C; Yáñez JA; Forrest ML; Davies NM
    J Pharm Pharm Sci; 2014; 17(1):34-91. PubMed ID: 24735761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I).
    Chiou WL
    Clin Pharmacokinet; 1989 Sep; 17(3):175-99. PubMed ID: 2680213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.
    Kopić A; Benamara K; Piskernik C; Plaimauer B; Horling F; Höbarth G; Ruthsatz T; Dietrich B; Muchitsch EM; Scheiflinger F; Turecek M; Höllriegl W
    J Thromb Haemost; 2016 Jul; 14(7):1410-9. PubMed ID: 27371116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of a cellular pharmacodynamic model exhibiting sharp response sensitivity and tolerance.
    Siegel RA
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):87-101. PubMed ID: 17160695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of chirality on pharmacokinetics and pharmacodynamics.
    Crom WR
    Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S9-14. PubMed ID: 1530005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic/pharmacodynamic consequences of space flight.
    Derendorf H
    J Clin Pharmacol; 1994 Jun; 34(6):684-91. PubMed ID: 8083401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absorption, metabolism, and other factors that influence drug exposure in toxicology studies.
    Mayer PR
    Toxicol Pathol; 1995; 23(2):165-9. PubMed ID: 7569671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.
    Sahota T; Danhof M; Della Pasqua O
    Mutagenesis; 2016 May; 31(3):359-74. PubMed ID: 26970519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Qualitative pharmacokinetic modeling of drugs.
    Boyce R; Collins C; Horn J; Kalet IJ
    AMIA Annu Symp Proc; 2005; 2005():71-5. PubMed ID: 16779004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations on pharmacodynamics and pharmacokinetics: can everything be explained by the extent of drug binding to its receptor?
    Castañeda-Hernández G; Granados-Soto V
    Can J Physiol Pharmacol; 2000 Mar; 78(3):199-207. PubMed ID: 10721811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms.
    Court MH
    Vet Clin North Am Small Anim Pract; 2013 Sep; 43(5):1039-54. PubMed ID: 23890237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development.
    Voisin EM; Ruthsatz M; Collins JM; Hoyle PC
    Regul Toxicol Pharmacol; 1990 Oct; 12(2):107-16. PubMed ID: 2259752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.